Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Reported Earlier, Moderna And Mitsubishi Tanabe Pharma Partner To Promote mRNA Respiratory Vaccine Portfolio In Japan

Author: Benzinga Newsdesk | July 09, 2024 02:19am

Under the agreement, Moderna will handle the manufacturing, sales, medical education and distribution of its mRNA respiratory vaccines. Both companies will engage in activities to enable broad access to Moderna's mRNA respiratory portfolio to have the maximum impact on public health in Japan. The agreement has an initial term until March 31, 2029 and no further details on the financial terms of the deal are being disclosed.

Posted In: MRNA

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist